16 completed, 2 unknown. 6 Phase 1, 4 Phase 4, 3 Not applicable, 2 Early Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 4 | 4 | Completed 4 |
| Not applicable | 3 | Unknown 2, Completed 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow benserazide, levodopa drug combination: new trials by email Literature Review of benserazide, levodopa drug combination trials Research Report on benserazide, levodopa drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dopamine, Reward Learning and Sex Hormones Levodopa administration, Placebo administration - Hormonal Changes, Menstrual Cycle | Not applicable | Unknown | University Hospital Tuebingen | 90 | 2024-05-01 | 2024-05-09 |
| Molecular Basis of Loss Aversion single-dose madopar, single-dose propranolol, and single-dose placebo by order, single-dose madopar, single-dose placebo, and single-dose propranolol by order, single-dose propranolol, single-dose madopar, and single-dose placebo by order - Healthy | Not applicable | Unknown | Sir Run Run Shaw Hospital | 60 | 2023-09-18 | 2023-09-26 |
| Relative Bioavailability Study of HRG2010 in Healthy Subjects HRG2010 Capsule, Sinemet®, Madopar® - Parkinson's Disease | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2021-09-10 | 2025-05-16 |
| Dopamine and Brain Computer Interface Madopar, Placebo - Healthy Participants | Early Phase 1 | Completed | Max Planck Institute for Human Cognitive and Brain Sciences | 22 | 2017-10-01 | 2025-05-31 |
| Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease PR Oxycodone, Levodopa, Oxycodone Placebo - Parkinson Disease | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 67 | 2016-09-01 | 2026-05-04 |
| Mucuna Pruriens Therapy in Parkinson's Disease MP-Equivalent, MP-Low, MP+DDCI - Parkinson's Disease | Phase 2 | Completed | ASST Gaetano Pini-CTO | 18 | 2016-02-01 | 2016-10-05 |
| Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON Levodopa dispersible, Levodopa - Parkinson Disease | Phase 4 | Completed | Seoul National University Hospital | 40 | 2015-06-01 | 2021-05-07 |
| Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission 200 mg levodopa/50 mg benserazide, Dextrose - Healthy, Schizotypal Personality | Early Phase 1 | Completed | University of Zurich | 65 | 2014-05-15 | 2017-11-06 |
| Levodopa Benserazide Generic Formulation Versus the Originator Levodopa Benserazide Madopar, Levodopa Benserazide Teva Italia - Parkinson Disease | Phase 4 | Completed | IRCCS San Raffaele Roma | 44 | 2014-04-01 | 2024-04-10 |
| Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke Levodopa, Virtual Reality based therapy - Ischaemic Stroke | Phase 3 | Completed | Singapore General Hospital | 9 | 2014-01-01 | 2017-02-10 |
| Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25 - Parkinson's Disease (PD) | Phase 1 | Completed | Bial - Portela C S.A. | 74 | 2010-02-01 | 2015-12-24 |
| Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers Levodopa + benserazide - Healthy Volunteers | Phase 4 | Completed | University of Buenos Aires | 24 | 2009-08-01 | 2011-08-04 |
| Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide BIA 9-1067, Placebo, levodopa/carbidopa - Parkinson Disease | Phase 1 | Completed | Bial - Portela C S.A. | 52 | 2009-03-01 | 2015-11-16 |
| Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide BIA 9-1067, Placebo, Prolopa® - Parkinson's Disease (PD) | Phase 1 | Completed | Bial - Portela C S.A. | 16 | 2008-09-01 | 2015-01-15 |
| Effect of Dopaminergic Medication on Recovery of Aphasia levodopa and benserazide, placebo - Aphasia | Not applicable | Completed | University Hospital, Geneva | 12 | 2007-02-01 | 2014-12-03 |
| Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg Placebo, BIA 6-512, Madopar® 250 - Parkinson Disease | Phase 1 | Completed | Bial - Portela C S.A. | 38 | 2006-07-17 | 2017-03-31 |
| Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide BIA 3-202, Placebo, levodopa 100 mg / benserazide 25 mg - Parkinson's Disease (PD) | Phase 1 | Completed | Bial - Portela C S.A. | 17 | 2005-09-01 | 2016-06-14 |
| Effect of Levodopa on Human Multifocal Electroretinogram levodopa - Retinal Diseases | Phase 4 | Completed | Medical University of Vienna | 20 | 2001-10-01 | 2008-12-22 |
Parkinson Disease (10) · Aphasia (1) · Ischemic Stroke (1) · Retinal Diseases (1) · Schizotypal Personality Disorder (1) · Stroke (1)
Bial - Portela C S.A. (5) · ASST Gaetano Pini-CTO (1) · IRCCS San Raffaele Roma (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Max Planck Institute for Human Cognitive and Brain Sciences (1) · Medical University of Vienna (1) · Seoul National University Hospital (1) · Singapore General Hospital (1) · Sir Run Run Shaw Hospital (1) · University Hospital Tuebingen (1) · University Hospital, Geneva (1) · University Hospital, Toulouse (1) · University of Buenos Aires (1) · University of Zurich (1)
Canada (2) · China (2) · France (2) · Germany (2) · Portugal (2) · Switzerland (2) · Austria (1) · Bolivia (1) · Italy (1) · Singapore (1) · South Korea (1)
Armin Schniider, Prof (1) · Arno Villringer, PhD (1) · Bernhard Sehm, PhD (1) · Eric Sicard, MD (1) · Gianni Pezzoli, MD (1) · Guillermo Di Girolamo, MD, PhD (1) · Jee-Young Lee, MD, PhD (1) · Khosrov A. Grigoryan, MSc (1) · Michael Wolzt, MD (1) · Nils B Kroemer, Professor (1) · Roberto Cilia, MD (1) · Yee S NG, MBBS, MRCP (1)
PMID 15372588, PMID 16805724, PMID 20332641, PMID 21635995, PMID 28679598, PMID 29352722, PMID 35148289, PMID 38850081